Physician profile
Julia Perkins
NPI 1235752841
$4,129.65
in general payments reported to CMS, 2019-2025
24 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.68 · 2022: $374 · 2023: $1,218 · 2024: $1,481 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,738.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $840.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $729.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $555.99 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $311.21 | 2023-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $238.86 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $230.92 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.89 | 2022-2023 | Synjardy, Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $175.27 | 2023-2025 | |
| Pfizer INC. | $154.59 | 2023-2025 | |
| Corcept Therapeutics | $134.72 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $109.46 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.91 | 2023-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $66.02 | 2023-2024 | Austedo Xr, Uzedy |
| Xeris Pharmaceuticals, INC. | $59.59 | 2024-2025 | Gvoke Hypopen |
| Lundbeck LLC | $52.92 | 2023-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.29 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $34.86 | 2024 | Verquvo |
| Sumitomo Pharma America, INC. | $24.82 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $21.01 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $19.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.98 | 2024 | Eliquis |
| Abbvie INC. | $17.68 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.98 | 2025 | |
| Ironwood Pharmaceuticals, INC | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.